EUVIMEDEUVIMED entdecken
Übersichtsarbeit

An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer

Karen M Yun iD, Ezra E W Cohen

JCO Oncology Practice · 2024

DOI: 10.1200/op.23.00747 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Karen M Yun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thyroid carcinomas comprise distinct pathologic subtypes. However, advancements in characterizing the molecular tumorigenesis of thyroid cancers have changed the treatment paradigm in the past decade. Genetic profiling has become an integral component of personalizing cancer care. Oral kinase inhibitors are currently standard-of-care therapies for progressive, radioactive iodine (RAI)–refractory differentiated thyroid carcinomas (DTCs) and medullary thyroid carcinomas (MTCs). Sorafenib, lenvatinib, and cabozantinib are multikinase inhibitors approved for patients with metastatic RAI-refractory DTC, whereas vandetanib and cabozantinib are approved for patients with MTC. Management of thyroid carcinomas has evolved such that targeted therapies have become therapeutic options for patients with BRAF , RET , NTRK , ALK , and ROS1 alterations and even have reported efficacy in anaplastic thyroid carcinomas. In this article, we review the advances made over the years in the treatment of metastatic thyroid carcinoma and focus on the systemic therapies that have recently transformed the treatment landscape of advanced disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansProtein Kinase InhibitorsAntineoplastic AgentsMolecular Targeted Therapy

Substanzen

Protein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, CA.

ORCID-Profile: Karen M Yun

Zitieren

APA

Yun, K. M., & Cohen, E. E. W. (2024). An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncology Practice. https://doi.org/10.1200/op.23.00747

Vancouver

Yun KM, Cohen EEW. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer. JCO Oncology Practice. 2024. doi:10.1200/op.23.00747

BibTeX
@article{Yun2024,
  author = {Yun, Karen M and Cohen, Ezra E W},
  title = {An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.23.00747}
}
Kostenlos starten →